Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

Salaün, Pierre‐Yves; Campion, L.; Bournaud, Claire; Faivre-Chauvet, Alain; Vuillez, Jean‐Philippe; Taïeb, David; Ansquer, C.; Rousseau, Caroline; Borson‐Chazot, Françoise; Bardet, Stéphane; Oudoux, A.; Cariou, Bertrand; Mirallié, Éric; Chang, Chien‐Hsing; M. Sharkey, Robert; M. Goldenberg, David; Chatal, Jean‐François; Barbet, Jacques; Kraeber‐Bodéré, Françoise

doi:10.2967/jnumed.111.101865

Public

Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

Published in Journal of Nuclear Medicine • Jun 28, 2012

Authors:

Pierre‐Yves Salaün

L. Campion

Claire Bournaud

Abstract

UNLABELLED: The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs). This prospective phase II multicenter trial evaluated the efficacy and safety of anti-...

Subject

Medicine

Radioimmunotherapy

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!